Brief: Castle Biosciences' Idgenetix Show Significant Improvement In Medication Response In Patients With Major Depressive Disorder
31/05/2023 12:34
May 31 (Reuters) - Castle Biosciences Inc CSTL.O :
* IDGENETIX® SHOWN TO SIGNIFICANTLY IMPROVE MEDICATION
RESPONSE
AND REMISSION RATES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Source text for Eikon: ID:nBwZ9lG5a
Further company coverage: CSTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million